Utkarsha A Singh, PhD

LWW •

Treatment Patterns of Bone-targeting Agents Among Solid... : American Journal of Clinical Oncology

*EpidStrategies, a Division of ToxStrategies, Inc., Katy, TX
†Center for Observational Research, Amgen Inc., Thousand Oaks, CA
‡Department of Medical Affairs, Amgen Inc., Thousand Oaks, CA
§University of Pennsylvania, Pennsylvania Hospital, Philadelphia, PA
The data sets generated and analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
This study was funded by Amgen Inc., Thousand O...

Epidemiology and Management of Immune Thrombocytopenia in Adult Patients in Algeria: A Non-interventional, Longitudinal, Nationwide Estimation Study | Asian Pacific Journal of Cancer Biology

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a transient or persistent decrease in platelet count (<100×103/mm3) [1-3]. The annual incidence of ITP is estimated at 1.9–6.4 per 100,000 children and 3.3 per 100,000 adults [4]. Among the adult patient population, the incidence of ITP is higher in women than in men, with the incidence rate increasing with age. Studies from the United Kingdom (UK), France, Taiwan, and Korea reported an incidence of 3.03–6.0/100,000 person-y...

Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT)

Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody, selective for fibroblast growth factor receptor 2b (FGFR2b). In FIGHT, bemarituzumab + mFOLFOX6 demonstrated clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with placebo + mFOLFOX6 among patients with FGFR2b-overexpressing GC (primary analysis data cutoff: September 23, 2020); here, we report the FIGHT final analysis (24 months after the last patient was enrolled).